505 related articles for article (PubMed ID: 26910900)
21. PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels.
Kim RY; Pless SA; Kurata HT
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9702-E9711. PubMed ID: 29078287
[TBL] [Abstract][Full Text] [Related]
22. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
23. Heteromeric Assembly of Truncated Neuronal Kv7 Channels: Implications for Neurologic Disease and Pharmacotherapy.
Li J; Maghera J; Lamothe SM; Marco EJ; Kurata HT
Mol Pharmacol; 2020 Sep; 98(3):192-202. PubMed ID: 32580997
[TBL] [Abstract][Full Text] [Related]
24. Calmodulin orchestrates the heteromeric assembly and the trafficking of KCNQ2/3 (Kv7.2/3) channels in neurons.
Liu W; Devaux JJ
Mol Cell Neurosci; 2014 Jan; 58():40-52. PubMed ID: 24333508
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
[TBL] [Abstract][Full Text] [Related]
26. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Zhou P; Yu H; Gu M; Nan FJ; Gao Z; Li M
Proc Natl Acad Sci U S A; 2013 May; 110(21):8726-31. PubMed ID: 23650395
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.
Miceli F; Soldovieri MV; Ambrosino P; Manocchio L; Mosca I; Taglialatela M
Curr Med Chem; 2018; 25(23):2637-2660. PubMed ID: 29022505
[TBL] [Abstract][Full Text] [Related]
29. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits.
Miceli F; Soldovieri MV; Ambrosino P; De Maria M; Migliore M; Migliore R; Taglialatela M
J Neurosci; 2015 Mar; 35(9):3782-93. PubMed ID: 25740509
[TBL] [Abstract][Full Text] [Related]
30. Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity.
Musella S; Carotenuto L; Iraci N; Baroli G; Ciaglia T; Nappi P; Basilicata MG; Salviati E; Barrese V; Vestuto V; Pignataro G; Pepe G; Sommella E; Di Sarno V; Manfra M; Campiglia P; Gomez-Monterrey I; Bertamino A; Taglialatela M; Ostacolo C; Miceli F
J Med Chem; 2022 Aug; 65(16):11340-11364. PubMed ID: 35972998
[TBL] [Abstract][Full Text] [Related]
31. Attenuating M-current suppression in vivo by a mutant Kcnq2 gene knock-in reduces seizure burden and prevents status epilepticus-induced neuronal death and epileptogenesis.
Greene DL; Kosenko A; Hoshi N
Epilepsia; 2018 Oct; 59(10):1908-1918. PubMed ID: 30146722
[TBL] [Abstract][Full Text] [Related]
32. Time-limited alterations in cortical activity of a knock-in mouse model of KCNQ2-related developmental and epileptic encephalopathy.
Biba-Maazou N; Becq H; Pallesi-Pocachard E; Sarno S; Granjeaud S; Montheil A; Kurz M; Villard L; Milh M; Santini PL; Aniksztejn L
J Physiol; 2022 May; 600(10):2429-2460. PubMed ID: 35389519
[TBL] [Abstract][Full Text] [Related]
33. Epilepsy phenotype and response to KCNQ openers in mice harboring the Kcnq2 R207W voltage-sensor mutation.
Tian F; Cao B; Xu H; Zhan L; Nan F; Li N; Taglialatela M; Gao Z
Neurobiol Dis; 2022 Nov; 174():105860. PubMed ID: 36113748
[TBL] [Abstract][Full Text] [Related]
34. The anticonvulsant retigabine suppresses neuronal K
Stas JI; Bocksteins E; Jensen CS; Schmitt N; Snyders DJ
Sci Rep; 2016 Oct; 6():35080. PubMed ID: 27734968
[TBL] [Abstract][Full Text] [Related]
35. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
Wuttke TV; Seebohm G; Bail S; Maljevic S; Lerche H
Mol Pharmacol; 2005 Apr; 67(4):1009-17. PubMed ID: 15662042
[TBL] [Abstract][Full Text] [Related]
36. A knock-in mouse model for KCNQ2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment.
Milh M; Roubertoux P; Biba N; Chavany J; Spiga Ghata A; Fulachier C; Collins SC; Wagner C; Roux JC; Yalcin B; Félix MS; Molinari F; Lenck-Santini PP; Villard L
Epilepsia; 2020 May; 61(5):868-878. PubMed ID: 32239694
[TBL] [Abstract][Full Text] [Related]
37. Reduced axonal surface expression and phosphoinositide sensitivity in K
Kim EC; Zhang J; Pang W; Wang S; Lee KY; Cavaretta JP; Walters J; Procko E; Tsai NP; Chung HJ
Neurobiol Dis; 2018 Oct; 118():76-93. PubMed ID: 30008368
[TBL] [Abstract][Full Text] [Related]
38. A conserved threonine in the S1-S2 loop of KV7.2 and K V7.3 channels regulates voltage-dependent activation.
Füll Y; Seebohm G; Lerche H; Maljevic S
Pflugers Arch; 2013 Jun; 465(6):797-804. PubMed ID: 23271449
[TBL] [Abstract][Full Text] [Related]
39. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy.
Orhan G; Bock M; Schepers D; Ilina EI; Reichel SN; Löffler H; Jezutkovic N; Weckhuysen S; Mandelstam S; Suls A; Danker T; Guenther E; Scheffer IE; De Jonghe P; Lerche H; Maljevic S
Ann Neurol; 2014 Mar; 75(3):382-94. PubMed ID: 24318194
[TBL] [Abstract][Full Text] [Related]
40. Made for "anchorin": Kv7.2/7.3 (KCNQ2/KCNQ3) channels and the modulation of neuronal excitability in vertebrate axons.
Cooper EC
Semin Cell Dev Biol; 2011 Apr; 22(2):185-92. PubMed ID: 20940059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
